Bristol-Myers Squibb Company (BMY) · page 77 of 197
Uses a reductio ad absurdum argument to challenge the company's valuation narrative.
Activist deck · expose_contradiction · expose_contradiction · overcrowded density
Slide locked Sign in to view
Slide schematic 8/8
callout 1/1 paragraph 3/3 source-note 1/1 table 1/1 title 2/2
Components 8
primary paragraph paragraph paragraph source-note data action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1